Back to top
more

Novavax (NVAX)

(Delayed Data from NSDQ)

$9.35 USD

9.35
4,422,333

-0.26 (-2.71%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $9.42 +0.07 (0.75%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

3 Biotech Stocks Likely to Gain as Coronavirus Spreads

by Zacks Equity Research

Here we discuss three biotech stocks, which are likely to benefit in case there is an outbreak of coronavirus infection in China.

The Zacks Analyst Blog Highlights: Novavax, NanoViricides, Aethlon Medical and Oncolytics Biotech

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Novavax, NanoViricides, Aethlon Medical and Oncolytics Biotech

Company News for Jan 22, 2020

by Zacks Equity Research

Companies in the news are: NVAX, UBER, CSS, VIVE

Options Traders Expect Huge Moves in Novavax (NVAX) Stock

by Zacks Equity Research

Investors need to pay close attention to Novavax (NVAX) stock based on the movements in the options market lately.

Tirthankar Chakraborty headshot

Coronavirus Infects Wall Street: Stocks to Gain & Lose

by Tirthankar Chakraborty

While travel-related stocks were hit hard on concerns over coronavirus, experimental vaccine companies rallied.

Novavax Rises on Fast Track Designation to Influenza Vaccine

by Zacks Equity Research

The FDA bestows a Fast Track Designation on Novavax's (NVAX) influenza vaccine candidate NanoFlu for adults aged 65 years and older. Shares rally.

Options Traders Expect Huge Moves in Novavax (NVAX) Stock

by Zacks Equity Research

Investors need to pay close attention to Novavax (NVAX) stock based on the movements in the options market lately.

Will Novavax (NVAX) Report Negative Q3 Earnings? What You Should Know

by Zacks Equity Research

Novavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Novavax Begins Phase III Study on Influenza Vaccine Candidate

by Zacks Equity Research

Novavax (NVAX) starts a pivotal late-stage study on its pipeline candidate NanoFlu influenza vaccine in senior patients. Shares up.

Zacks.com featured highlights include: Odonate Therapeutics, Novavax, Beazer Homes USA and NVIDIA

by Zacks Equity Research

Zacks.com featured highlights include: Odonate Therapeutics, Novavax, Beazer Homes USA and NVIDIA

Tirthankar Chakraborty headshot

4 of the Best Stocks With Solid Earnings Acceleration

by Tirthankar Chakraborty

Studies have shown that a majority of successful stocks see acceleration in earnings before an uptick in the stock price.

Are Options Traders Betting on a Big Move in Novavax (NVAX) Stock?

by Zacks Equity Research

Investors need to pay close attention to Novavax (NVAX) stock based on the movements in the options market lately.

Zacks.com featured highlights include: Novavax, The Cooper Companies, Veeco Instruments and Maxar Technologies

by Zacks Equity Research

Zacks.com featured highlights include: Novavax, The Cooper Companies, Veeco Instruments and Maxar Technologies

Tirthankar Chakraborty headshot

4 Stocks That Boast Superb Earnings Acceleration

by Tirthankar Chakraborty

Studies have shown that a majority of stocks had seen acceleration in earnings before a rally in stock price.

Novavax, Inc. (NVAX) Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Novavax, Inc. (NVAX).

Implied Volatility Surging for Novavax (NVAX) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Novavax (NVAX) stock based on the movements in the options market lately.

Novavax (NVAX) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Novavax (NVAX) delivered earnings and revenue surprises of -4.97% and -4.98%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Novavax (NVAX) Seeks Accelerated Approval Pathway for NanoFlu

by Zacks Equity Research

Novavax (NVAX) seeks to use accelerated approval pathway for its influenza vaccine candidate, NanoFlu, in the United States.

Will Novavax Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor Novavax.

Novavax Enters Oversold Territory

by Zacks Equity Research

Novavax, Inc. (NVAX) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Novavax' Shares Drop as FDA Advises Another Study for Resvax

by Zacks Equity Research

FDA recommends Novavax (NVAX) to conduct additional phase III study for its respiratory syncytial virus (RSV) vaccine candidate for infants, ResVax.

Novavax (NVAX) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Novavax (NVAX) delivered earnings and revenue surprises of 8.33% and -17.04%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Is the Options Market Predicting a Spike in Novavax (NVAX) Stock?

by Zacks Equity Research

Investors need to pay close attention to Novavax (NVAX) stock based on the movements in the options market lately.

What's in the Cards for Novavax (NVAX) This Earnings Season?

by Zacks Equity Research

Novavax (NVAX) is likely to provide update on the path forward for its two lead vaccine candidates.

Zacks Value Trader Highlights: Novavax, J.C. Penney, Pier 1 Imports, Tilray and Aurora Cannabis

by Zacks Equity Research

Zacks Value Trader Highlights: Novavax, J.C. Penney, Pier 1 Imports, Tilray and Aurora Cannabis